---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028369"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-06-12T11:30:20+00:00"
generated_at: "2026-06-12T11:35:42.362093+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics director Michael Amoroso resigns from board for personal reasons

## Summary
- Michael Amoroso resigned from Abeona's Board effective June 11, 2026.
- He also stepped down from the Nominating and Corporate Governance Committee.
- Resignation was for personal reasons; no disagreement with company operations.
- No replacement named; board size reduced accordingly.

## SEC filing metadata
- accession: 0001493152-26-028369
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-06-12T11:30:20+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/0001493152-26-028369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028369
- JSON: https://secwatch.observer/filing/0001493152-26-028369.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028369.txt

## Key facts
- Executive change
  Michael Amoroso resigned as Director at ABEONA THERAPEUTICS INC..
  - Action: resigned
  - Role: Director
  source text: On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/0001493152-26-028369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.